RxDoctor Payments Data

Jennifer Young, NP

Gerontology · Galveston, TXNPI 1679966477

Payments from drug & device makers

$1,761in general payments, 2019–2025

Across 21 payments — averaging $83.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$202
  • Alnylam Pharmaceuticals Inc.$146
  • Madrigal Pharmaceuticals$140
  • Novo Nordisk$124
  • AstraZeneca$124
  • Gilead$122
  • plus $904 from 11 others

What the payments were for

  • Food & beverage$1,761100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,761 in reported general payments places this provider in the 75th percentile of 653 gerontology providers in Texas.

See all gerontology providers in Texas

Medicare billing

Part B allowed, 2024
$72,353
Medicare patients
108
Services billed
769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban102$60,886
EntrestoSacubitril/Valsartan29$24,064
XareltoRivaroxaban21$16,755
MyrbetriqMirabegron19$9,160
FarxigaDapagliflozin Propanediol11$6,741
Duloxetine Hcl80$3,902
LumiganBimatoprost12$3,160
Trospium Chloride43$2,854
Buspirone Hcl178$2,819
Memantine Hcl51$2,776
Levothyroxine Sodium239$2,370
Atorvastatin Calcium153$1,911
Mirtazapine74$1,882
Midodrine Hcl19$1,798
Vilazodone Hcl13$1,661

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$124$6,74111 claims
AbbVieLumigan$202$3,16012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 653 gerontology providers in Texas.

Other gerontology in Galveston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →